- Home
- ACIC vs ERAS Comparison
ACIC vs ERAS Comparison
Compare ACIC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- ERAS
- Stock Information
- Founded
- ACIC 1999
- ERAS 2018
- Country
- ACIC United States
- ERAS United States
- Employees
- ACIC N/A
- ERAS N/A
- Industry
- ACIC Property-Casualty Insurers
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- ERAS Health Care
- Exchange
- ACIC Nasdaq
- ERAS Nasdaq
- Market Cap
- ACIC 605.0M
- ERAS 719.0M
- IPO Year
- ACIC N/A
- ERAS 2021
- Fundamental
- Price
- ACIC $12.72
- ERAS $3.19
- Analyst Decision
- ACIC Buy
- ERAS Strong Buy
- Analyst Count
- ACIC 1
- ERAS 5
- Target Price
- ACIC $15.00
- ERAS $6.10
- AVG Volume (30 Days)
- ACIC 275.2K
- ERAS 1.5M
- Earning Date
- ACIC 11-06-2024
- ERAS 11-15-2024
- Dividend Yield
- ACIC N/A
- ERAS N/A
- EPS Growth
- ACIC N/A
- ERAS N/A
- EPS
- ACIC 1.76
- ERAS N/A
- Revenue
- ACIC $290,784,000.00
- ERAS N/A
- Revenue This Year
- ACIC N/A
- ERAS N/A
- Revenue Next Year
- ACIC $12.98
- ERAS N/A
- P/E Ratio
- ACIC $7.24
- ERAS N/A
- Revenue Growth
- ACIC N/A
- ERAS N/A
- 52 Week Low
- ACIC $6.82
- ERAS $1.51
- 52 Week High
- ACIC $14.38
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- ACIC 61.32
- ERAS 67.35
- Support Level
- ACIC $11.86
- ERAS $2.59
- Resistance Level
- ACIC $13.52
- ERAS $3.25
- Average True Range (ATR)
- ACIC 0.59
- ERAS 0.20
- MACD
- ACIC 0.18
- ERAS 0.06
- Stochastic Oscillator
- ACIC 79.07
- ERAS 97.53
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary. The company has two segments namely: Commercial Lines Business and Personal Lines Business. It derives maximum revenue from Commercial Lines Business Segment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.